Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: Long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group

Haematologica

Volumn 99, Issue 1, 2014, Pages 46-53

  Bertoli, Sarah ^a   Bories, Pierre ^b   Béné, Marie C ^c   Daliphard, Sylvie ^d   Lioure, Bruno ^b   Pigneux, Arnaud ^e   Vey, Norbert ^f   Delaunay, Jacques ^c   Leymarie, Vincent ^b   Luquet, Isabelle ^d   Blanchet, Odile ^g   Cornillet Lefebvre, Pascale ^d   Hunault, Mathilde ^h   Bouscary, Didier ⁱ   Fegueux, Nathalie ^j   Guardiola, Philippe ^h   Dreyfus, François ⁱ   Harousseau, Jean Luc ^k   Cahn, Jean Yves ^l   Ifrah, Norbert ^h   Récher, Christian ^a   more..

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d REIMS UNIVERSITY HOSPITAL   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f INSTITUT PAOLI CALMETTES   (France)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h ANGERS UNIVERSITY HOSPITAL   (France)

ⁱ APHP Cochin ^*  (France)

^j MONTPELLIER UNIVERSITY HOSPITAL   (France)

^k CENTRE RENÉ GAUDUCHEAU   (France)

^l GRENOBLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHROMOSOME ABERRATIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892601073     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.091819     Document Type: Article

References (30)

1. Preisler HD, Rustum Y, Henderson ES, Bjornsson S, Creaven PJ, Higby DJ, et al. Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Blood. 1979;53(3):455-64.
2. Yates JW, Wallace HJ Jr, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973; 57(4):485-8.
3. Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487-94.
4. Rowe JM. Is there a role for intensifying induction therapy in acute myeloid leukaemia (AML)? Best Pract Res Clin Haematol. 2009;22(4):509-15.
5. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13): 1249-59.
6. Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235-48.
7. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.
8. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475-86.
9. Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Childhood and adolescent lymphoid and myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004:118-45.
10. Panzer-Grümayer ER, Schneider M, Panzer S, Fasching K, Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood. 2000;95(3):790-4.
11. Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunoru-bicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93(12):4116-24.
12. Preisler HD, Rustum YM. Prediction of therapeutic response in acute myelocytic leukemia. Haematol Blood Transfus. 1979;23:93-8.
13. Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood. 2003;101(1):64-70.
14. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999;107 (1):69-79.
15. Anderlini P, Ghaddar HM, Smith TL, Pierce S, Kantarjian HM, O'Brien S, et al. Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. Leukemia. 1996;10(6):964-9.
16. Lioure B, Bene MC, Pigneux A, Huynh A, Chevallier P, Fegueux N, et al. Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. Blood. 2012;119(12):2943-8.
17. Chevallier P, Fornecker L, Lioure B, Béné MC, Pigneux A, Recher C, et al. Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial. Leukemia. 2010;24(7):1380-5.
18. Brothman AR, Persons DL, Shaffer LG. Nomenclature evolution: Changes in the ISCN from the 2005 to the 2009 edition. Cytogenetic Genome Res. 2009;127(1):1-4.
19. Leymarie V, Flandrin G, Noguera ME, Leymarie F, Lioure B, Daliphard S. Telehematology: a pilot experience of cyto-logical diagnosis of acute myeloid leukemia via the Internet. A GOELAMS study. Haematologica. 2006;91(9):1285-6.
20. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-9.
21. Büchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitox-antrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol. 2006;24 (16):2480-9.
22. Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, et al. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood. 2009;113(21):5250-3.
23. Rowe JM, Kim HT, Cassileth PA, Lazarus HM, Litzow MR, Wiernik PH, et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer. 2010;116(21):5012-21.
24. Heil G, Krauter J, Raghavachar A, Bergmann L, Hoelzer D, Fiedler W, et al. Risk-adapted induction and consolidation therapy in adults with de novo AML aged
25. Elliott MA, Litzow MR, Letendre LL, Wolf RC, Hanson CA, Tefferi A, et al. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood. 2007;110(13):4172-4.
26. Lacombe F, Arnoulet C, Maynadie M, Lippert E, Luquet I, Pigneux A, et al. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study. Leukemia. 2009;23(2):350-7.
27. Braess J, Spiekermann K, Staib P, Grüneisen A, Wörmann B, Ludwig WD, et al. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood. 2009;113(17):3903-10.
28. Nerich V, Lioure B, Rave M, Recher C, Pigneux A, Witz B, et al. Induction-related cost of patients with acute myeloid leukaemia in France. Int J Clin Pharm. 2011;33(2):191-9.
29. Liso V, Albano F, Pastore D, Carluccio P, Mele G, Lamacchia M, et al. Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia. Haematologica. 2000;85(12):1285-90.
30. Yanada M, Borthakur G, Ravandi F, Bueso-Ramos C, Kantarjian H, Estey E. Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. Haematologica. 2008;93(8):1263-5.